Richard K. Prins Sells 10,000 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $43.77, for a total transaction of $437,700.00. Following the transaction, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $44.50 on Friday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm’s fifty day moving average is $47.22 and its 200 day moving average is $44.62. The company has a market cap of $2.14 billion, a price-to-earnings ratio of 14.83, a PEG ratio of 0.87 and a beta of 0.78.

Analyst Ratings Changes

Several analysts have commented on the stock. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target on the stock. StockNews.com downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $60.33.

Institutional Trading of Amphastar Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its position in Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the period. Innealta Capital LLC bought a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $55,000. Blue Trust Inc. raised its holdings in Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares during the period. Finally, Asset Management One Co. Ltd. bought a new stake in Amphastar Pharmaceuticals in the third quarter worth $78,000. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.